Bio­gen CEO Michel Vounatsos re­groups and stakes out a BD plan for 2017

Bio­gen’s new CEO showed up at JP Mor­gan to ral­ly sup­port for the com­pa­ny’s pipeline and raise the prospect of ex­e­cut­ing a few new deals in 2017.

CEO Michel Vounatsos saw rea­son for en­cour­age­ment for the fu­ture of ad­u­canum­ab af­ter Eli Lil­ly’s solanezum­ab failed a huge Phase III ef­fort in Alzheimer’s, ac­cord­ing to Leerink an­a­lyst Ge­of­frey Porges’ sum­ma­ry of his pre­sen­ta­tion. Bio­gen’s part­ner Ei­sai, mean­while, plans to put out da­ta on their an­ti-amy­loid an­ti­body BAN2401 in the next 12-18 months. An oral BACE pro­gram for elen­be­ce­s­tat (aka E2609) has got un­der­way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER